ReviewWorld journal of hepatology2020
Update on diagnosis and management of sepsis in cirrhosis: Current advances.
Review in World journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Critical Illness-Related Alterations in Plasma Phosphatidylcholine Species Reveal Selective Induction of PC 32:0.International journal of molecular sciences · 2026Article
- Novel Insights on Clinical Outcomes Using Integrated Shotgun Metagenomic Profiling of the Gut Microbiome, Resistome, and Host Immune-Inflammatory Response in Hospitalized Patients with Decompensated Cirrhosis.Pathogens (Basel, Switzerland) · 2026Article
- Clinical implications of a dynamic nomogram for predicting sepsis in acute liver failure.World journal of gastroenterology · 2026Article
- A Prognostic Model Based on Immune-Inflammatory-Nutritional Indicators for 28-Day Mortality in Sepsis Patients with Acute-on-Chronic Liver Failure.Journal of inflammation research · 2026Article
- Development and validation of a prediction model for in-hospital mortality in intensive care unit patients with cirrhosis and sepsis: a multicentre retrospective cohort study.Frontiers in medicine · 2026Article
- Infection risk and management in patients with cirrhosis: A critical overview.World journal of hepatology · 2025Article
- Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda.Hepatology communications · 2024Review
- Fast Track Diagnostic Tools for Clinical Management of Sepsis: Paradigm Shift from Conventional to Advanced Methods.Diagnostics (Basel, Switzerland) · 2023Review
- Relationship Between Etiology of Cirrhosis and Survival Among Patients Hospitalized in Intensive Care Units.Mayo Clinic proceedings · 2022Article
- Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients.Journal of clinical and translational hepatology · 2021Review
- Hepatorenal syndrome in acute-on-chronic liver failure with acute kidney injury: more questions requiring discussion.Gastroenterology report · 2021Review
- Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study.BMJ open gastroenterology · 2021Article
- Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care.Journal of clinical and translational hepatology · 2021Review
- Article
- Gut Barrier and Microbiota in Cirrhosis.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis and septic shock are catastrophic disease entities that portend high mortality in patients with cirrhosis. In cirrhosis, hemodynamic perturbations, immune dysregulation, and persistent systemic inflammation with altered gut microbiota in the background of portal hypertension enhance the risk of infections and resistance to antimicrobials. Patients with cirrhosis develop recurrent life-threatening infections that progress to multiple organ failure. The definition, pathophysiology, and treatment options for sepsis have been ever evolving. In this exhaustive review, we discuss novel advances in the understanding of sepsis, describe current and future biomarkers and scoring systems for sepsis, and delineate newer modalities and adjuvant therapies for the treatment of sepsis from existing literature to extrapolate the same concerning the management of sepsis in cirrhosis. We also provide insights into the role of gut microbiota in initiation and progression of sepsis and finally, propose a treatment algorithm for management of sepsis in patients with cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.